One Wealth Advisors LLC Makes New $1.49 Million Investment in McKesson Corporation $MCK

Key Points

• One Wealth Advisors acquired 1,977 McKesson shares worth approximately $1.49 million in the second quarter. Institutional investors and hedge funds collectively own 85.07% of the company.
• McKesson reported quarterly EPS of $9.93, beating estimates of $9.56, while revenue rose 7.7% year over year to $105.38 billion. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $977.
• The company raised its quarterly dividend from $0.82 to $0.94 per share, equal to an annualized dividend of $3.76 and a 0.4% yield. Insiders have sold 29,049 shares valued at approximately $22.5 million over the past 90 days.

One Wealth Advisors LLC acquired a new stake in McKesson Corporation (NYSE:MCK - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 1,977 shares of the company's stock, valued at approximately $1,494,000.

A number of other large investors also recently modified their holdings of MCK. University of Texas Texas AM Investment Management Co. acquired a new position in McKesson during the 4th quarter worth $25,000. Swiss RE Ltd. acquired a new stake in shares of McKesson in the 4th quarter valued at $26,000. State of Wyoming acquired a new stake in shares of McKesson in the 2nd quarter valued at $29,000. Kingdom Financial Group LLC. bought a new stake in shares of McKesson during the fourth quarter worth $33,000. Finally, Birchwood Financial Partners Inc. acquired a new position in shares of McKesson during the fourth quarter valued at $33,000. 85.07% of the stock is currently owned by institutional investors and hedge funds.

McKesson Trading Up 1.4%

NYSE:MCK opened at $868.72 on Friday. McKesson Corporation has a 1-year low of $667.50 and a 1-year high of $999.00. The business's 50-day moving average price is $813.45 and its two-hundred day moving average price is $842.81. The firm has a market capitalization of $101.28 billion, a price-to-earnings ratio of 23.25, a PEG ratio of 1.71 and a beta of 0.30.

McKesson (NYSE:MCK - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $9.56 by $0.37. The firm had revenue of $105.38 billion for the quarter, compared to analysts' expectations of $103.88 billion. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%.The company's revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the business earned $8.26 earnings per share. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. Sell-side analysts predict that McKesson Corporation will post 44.65 earnings per share for the current year.

McKesson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Tuesday, September 1st will be issued a dividend of $0.94 per share. This is an increase from McKesson's previous quarterly dividend of $0.82. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Tuesday, September 1st. McKesson's dividend payout ratio is presently 8.78%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on MCK shares. Morgan Stanley reiterated an "overweight" rating on shares of McKesson in a report on Friday, August 7th. Citigroup boosted their price objective on McKesson from $945.00 to $1,000.00 and gave the stock a "buy" rating in a report on Friday, July 24th. UBS Group raised their target price on shares of McKesson from $1,050.00 to $1,080.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Evercore reiterated an "outperform" rating on shares of McKesson in a research report on Thursday, August 6th. Finally, Deutsche Bank Aktiengesellschaft reissued a "buy" rating and set a $875.00 price target on shares of McKesson in a research note on Friday, May 8th. Fourteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $977.00.

Insider Activity

In other news, EVP Michele Lau sold 3,550 shares of McKesson stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $761.09, for a total transaction of $2,701,869.50. Following the transaction, the executive vice president directly owned 3,247 shares of the company's stock, valued at $2,471,259.23. This trade represents a 52.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Thomas L. Rodgers sold 2,388 shares of the business's stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $761.09, for a total transaction of $1,817,482.92. Following the completion of the transaction, the executive vice president directly owned 3,090 shares of the company's stock, valued at $2,351,768.10. This trade represents a 43.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 29,049 shares of company stock valued at $22,530,626. 0.06% of the stock is currently owned by company insiders.

McKesson Company Profile

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source